GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

The recommended doses of GLP-1 can be taken daily or once a week, depending on the patient’s prescription. Health experts ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...

Diabetes, a condition where blood glucose levels cannot be ... inhibitors — these help a person’s pancreas produce more insulin and less glucagon, to reduce their blood glucose levels glucagon-like ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...